JPIAMR 14th Call Partner Search Tool

General Information

• Type: Partner looking for project
• Organisation: Institute of Phthisiopneumology
• Country: Moldova (MD)

Research area

• Scientific area(s) of the call:
  1. Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials
  2. Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials
• One Health Setting:

  Human Health

• Type of studies/experimental approaches:

  in silico, in vitro, in vivo

• Keywords:

  M.tuberculosis drug resistance mutations tuberculosis new treatment regimes molecular methods of diagnostic of resistance

• Brief description of your expertise / expertise you are looking for:

  The Institute of Phthisiopneumology (IPP) from Chisinau is the main research institution and republican clinical structure in the field of tuberculosis control from Moldova. The main research fields of the IPP include epidemiology, diagnosis, treatment of tuberculosis and nonspecific pulmonary diseases. The other scientific area of activities of Institute is new molecular genetic methods of diagnostic of pulmonary deceases, new therapeutic compounds with anti-TB activity, genotyping of M.tuberculosis, TB drug resistance, nosocomial transmission of TB. During last 10 years IPP implemented more of 50 national and international studies and projects, financed by National Institute of Health and National Institute of Allergy and Infectious Diseases (USA), USAID, Horisont2020, FP7 programs, Global Funds for AIDS, Tuberculosis and Malaria (GFATM), Stop TB Reach, FIND, WHO, European & Developing Countries Clinical Trials Partnership (EDCTP). The results of investigations have been published widely with over 1000 scientific publications in national and international journals. The laboratory has extensive collaborations with scientific partners from USA, Germany, France, Romania, United Kingdom, Netherlands, Leetonia, Russia, Ukraine and other countries. The list of publications and projects see on the site: https://www.researchgate.net/profile/Valeriu-Crudu; https://www.ncbi.nlm.nih.gov/myncbi/collections/mybibliography/?page=2

• Brief description of your project / the project you would like to join:

  Treatment of TB drug resistance is a major challenge for National Tuberculosis Programs (NTP) in high-burden settings. This is especially true in Eastern Europe, where a large proportion of all patients are resistant to several first-line medicines, and some patients are resistant to a wide range of first- and second-line medicines. In this case, identifying the drugs to which the patient is sensitive is essential for designing an effective treatment regimen. Phenotypic DST is an imperfect tool for this task, as the need to cultivate Mtb isolate introduces substantial delays that prolong the time before the start of an effective treatment regimen and may also be ineffective if resistance testing is required for a large number of drugs. The development of molecular tools has added a new dimension to the classical epidemiology of tuberculosis and has greatly improved the understanding of the complex dynamics of transmission within populations and between hosts. In this process, molecular epidemiology has shown shortcomings in TB control programs and has helped to build up motivation and resources to improve them.

Valeriu Crudu

• Organisation: Institute of Phthisiopneumology
• Position: Chief of National TB Reference Laboratory
• E-mail: valeriu.crudu@scm-md.com
• Phone: +373-69690111
• Web: ifp.md/en